1,525
Participants
Start Date
June 22, 2018
Primary Completion Date
October 31, 2022
Study Completion Date
October 31, 2026
Percutaneous coronary intervention
At the index procedure, the culprit lesion (cause of complaints/acute coronary syndrome) will be treated according to standard of care with a Biotronik Orsiro DES (Sirolimus-Eluting stent). If there are additional significant lesions besides the culprit lesion, patients will be randomized to direct complete revascularization or staged complete revascularization. In the direct complete revascularization group all lesions will be treated during the index procedure. In the staged complete revascularization group, only the culprit lesion will be treated during the index procedure. The remaining significant lesions will be treated later but within six weeks after the index procedure. In both arms the additional lesions will also be treated with Biotronik Orsiro DES (Sirolimus-Eluting stent).
Erasmus Medical Center, Rotterdam
Lead Sponsor
Biotronik SE & Co. KG
INDUSTRY
Erasmus Medical Center
OTHER